Our data demonstrates that intravenously administered nAlb conjugates bind to circulating albumin in situ, increasing nanobody half-life from minutes to days and harnessing the capacity of albumin to accumulate in tumors to delivery of cargo to cancer cells and tumor-associated myeloid cells in the TME. The gene discussed is ALB; the disease is cancer.